DWM
TGTX icon

Dogwood Wealth Management’s TG Therapeutics TGTX Stock Holding History

Dogwood Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$440 Buy
+8
New +$327 ﹤0.01% 812

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Dogwood Wealth Management's TGTX Position: Q2 2026 in Review

Dogwood Wealth Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 8 shares worth $440. The stake represents ﹤0.01% of the portfolio and ranks #812 among its holdings.

431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Dogwood Wealth Management held 8 shares of TG Therapeutics worth $440 as of Q2 2026.
  • TG Therapeutics was a new Dogwood Wealth Management position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Dogwood Wealth Management's portfolio in Q2 2026, its #812 holding.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Dogwood Wealth Management's 13F filing for Q2 2026, filed 6 Jul 2026.